Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Updates in Juvenile Dermatomyositis: Pathogenesis & Patient Care

Jason Liebowitz, MD, FACR  |  Issue: September 2021  |  July 17, 2021

PRSYM—Idiopathic inflammatory myopathy exists in both pediatric and adult populations. Although some features of the disease are similar across age groups, other elements of pathogenesis and treatment can differ. At the virtual 2021 Pediatric Rheumatology Symposium (PRSYM), a session on updates in juvenile dermatomyositis (JDM) provided a plethora of clinical pearls and insights into what we know about this condition.

Pathogenesis

Hanna Kim, MD, MS, assistant clinical investigator, Juvenile Myositis Pathogenesis and Therapeutics Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda, Md., discussed the pathogenesis of, and treatment options for, JDM.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Environmental ultraviolet (UV) light exposure may have a role in the pathogenesis of JDM. Dr. Kim noted that exposure to higher UV light index levels is associated with greater skin involvement in juvenile myositis. In non-Black patients with JDM, the odds of developing calcinosis are increased with exposure to higher UV light index levels in the month preceding symptom onset.

When evaluating muscle pathology, it appears vascular changes, hypoxia and a prominent interferon signature may be linked to histologic changes seen on muscle biopsy. Dr. Kim is the lead author of a study that showed peripheral blood interferon-regulated gene expression in JDM overlaps with that seen in monogenic interferonopathies, such as STING-associated vasculopathy with onset in infancy (SAVI), and correlates with disease activity.5

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Diagnosis

Ann Marie Reed, MD, Samuel L. Katz Distinguished Professor of Pediatrics and chair of the Department of Pediatrics, Duke University School of Medicine, Durham, N.C., centered her presentation on a young patient with JDM whom she has treated over the past several years.

When approaching any patient, particularly those with long, complicated medical histories and with care delivered at different locations, Dr. Reed said the first essential task is to verify the diagnosis. Review all past records and look for objective evidence of the disease in question, such as results from a muscle biopsy.

It’s important to know which medications were given, when they were given and what the effects of these treatments were. To paint the entire picture, laboratory studies and imaging are also essential, and it’s important to understand findings in the context of the epidemiology of the disease.

About 80% of patients with juvenile idiopathic inflammatory myopathy have dermatomyositis, Dr. Reed explained. Polymyositis is less frequently seen, with a prevalence of 4–8% and an increased prevalence in Black girls. Features of polymyositis may include severe weakness and cardiac involvement. Between 6 and 11% of patients with myositis demonstrate overlap with other connective tissue diseases, such as systemic lupus erythematosus, juvenile idiopathic arthritis or scleroderma.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsMeeting Reports Tagged with:juvenile dermatomyositisPathogenesisPediatric RheumatologyPediatric Rheumatology SymposiumPRSYM

Related Articles

    Inflammatory Myopathies in Children

    July 10, 2012

    Treatment options and recent research for juvenile dermatomyositis.

    New Tools for Myositis Diagnosis, Classification & Management

    April 15, 2019

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Oksana Kuzmina/shutterstock.comx

    Environmental Factors in Pediatric Systemic Autoimmune Diseases

    March 20, 2017

    Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…

    Autoantibodies in Autoimmune Myopathy

    Autoantibodies in Autoimmune Myopathy

    September 18, 2017

    In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences